The series sorts the three drugs by how many receptors each one targets, from one to three, and notes retatrutide is still under investigation. Two more peptides are promised.
Recap by typeshit. Post by Facebook on Facebook.
Avi Roy points out that the largest test so far found no memory benefit from the drug in Ozempic, despite hopes raised by health record studies.
Balwinder Singh and Raman Baweja link GLP-1 use to less kidney replacement therapy in bipolar patients with CKD, and flag lithium toxicity cases.
Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
24:26
A doctor's explainer sorting peptides into eight broad categories. An evergreen overview for anyone still learning the basics.
A Mayo Clinic Florida study of over 3,800 women found 9.8% vs 8.2% weight loss at 9 months with HT on semaglutide. Researchers say it shows association, not cause.
The same variant also raised odds of nausea and vomiting, and tirzepatide users carrying two variants had 14.8 times the odds of vomiting, researchers report.
Loading…